- New data from the Phase 2 OASIS trial and its open-label extension for etrasimod in ulcerative colitis - Arena sponsored symposium: Opening the Door to Emerging Investigational Treatments in Ulcerative Colitis: What Awaits Us? SAN DIEGO , Oct. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals,
- Evaluating 3 doses of olorinab in study participants with the clinical diagnosis of irritable bowel syndrome with predominant constipation (IBS-C) or diarrhea (IBS-D) - Topline data expected Q1 2021 - Significant unmet need for non-opioid, peripherally acting pain management in
SAN DIEGO , Sept. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on September 15, 2020 , the Compensation Committee of its Board of Directors granted to nine new employees inducement stock options to purchase an aggregate of 68,825 shares of its common
SAN DIEGO , Sept. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Wednesday, September
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderately to severely active ulcerative colitis (UC) - Significant unmet need for new effective oral therapies in UC SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
SAN DIEGO , Sept. 3, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that that members of its senior management team will participate in the upcoming investor conferences: Wells Fargo Virtual Healthcare Conference – Presenting on Wednesday, September 9 , at 1:20 PM
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderate-to-severe alopecia areata - There are currently no FDA-approved treatments for alopecia areata SAN DIEGO , Sept. 1, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first
SAN DIEGO , Aug. 19, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on August 15, 2020 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 15,275 shares of its common stock
- Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, topline data expected Q4 2020 - Progressing first- or best-in-class drug candidates with liquidity position of ~$1.3bn as of June 30, 2020 SAN DIEGO , Aug. 5, 2020 /PRNewswire/ -- Arena Pharmaceuticals,
SAN DIEGO , July 29, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2020 financial results and provide a corporate update on Wednesday, August 5, 2020 , after the close of the U.S. financial markets. The Company will host a question and answer